Phase II Trial of Nintedanib in Patients With Advanced Esophagogastric Cancer

Trial Profile

Phase II Trial of Nintedanib in Patients With Advanced Esophagogastric Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 May 2017

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 17 Jan 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
    • 27 Sep 2014 New source identified and integrated (Memorial Sloan-Kettering Cancer Center:14-094).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top